Oralair

Allergen extract from pollen of Dactylis glomerata, Anthoxanthum odoratum, Lolium perenne, Poa pratensis, the active ingredient in Oralair, is a allergen immunotherapy presented as a sublingual tablet for sublingual use. It treats seasonal allergic rhinitis and allergic rhinoconjunctivitis caused by grass pollen in patients with documented sensitivity.

GNH USA supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets. The company provides reliable logistics, documentation support, and post‑delivery service to meet the needs of healthcare providers.

Oralair is used in allergen immunotherapy to modify the immune response in grass‑pollen‑induced allergic disease.

Seasonal allergic rhinitis: reduces nasal congestion, sneezing and itching during grass pollen season. Allergic rhinoconjunctivitis: alleviates eye irritation, tearing and itching associated with grass pollen exposure. Grass pollen allergy: improves overall symptom control and reduces need for rescue medication.

Adverse reactions to Oralair are generally mild and related to local immune activation.

Common Side Effects: - Mild oral itching or tingling: transient sensation under the tongue. - Mouth swelling: slight edema that resolves without treatment. - Throat irritation: mild soreness after tablet placement. - Ear discomfort: occasional pressure sensation. - Nasal irritation: mild congestion or runny nose.

Serious or Rare Side Effects: - Anaphylaxis: severe systemic allergic reaction requiring immediate medical attention. - Angio‑edema: rapid swelling of lips, tongue or face. - Bronchospasm: difficulty breathing or wheezing. - Severe urticaria: widespread hives.

Before initiating Oralair, several safety considerations should be reviewed.

Medical evaluation: confirm grass‑pollen allergy with appropriate testing before initiating therapy. Age restriction: not recommended for children under the age specified by local labeling. Concurrent immunotherapy: avoid using other allergen immunotherapy products simultaneously. Pregnancy and lactation: discuss risks with healthcare provider as safety data are limited. Asthma control: ensure asthma is well‑controlled before starting sublingual treatment. Store at ambient temperature: keep tablets in original packaging, protect from moisture and direct sunlight.

Oralair may interact with certain medications; awareness helps manage risk.

Major Interactions (Avoid): - Beta‑blockers: may mask anaphylaxis symptoms and hinder emergency treatment. - ACE inhibitors: increase risk of angio‑edema during allergic reactions. - Concurrent subcutaneous allergen immunotherapy: higher chance of systemic reactions.

Moderate Interactions (Monitor Closely): - Antihistamines: may reduce local side effects but do not affect overall efficacy. - Corticosteroids: can be used to manage severe reactions without discontinuing therapy.